Form 4: Rhythm Pharmaceuticals Executive Yann Mazabraud Executes Stock Options and Sells Shares

Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 14, 2025, Yann Mazabraud, EVP, Head of International at Rhythm Pharmaceuticals, exercised stock options to acquire 75,000 shares of common stock at a price of $22.28 per share.
• Mazabraud then sold 19,197 shares at a weighted average price of $50.7916, with individual sales ranging from $50.31 to $51.26.
• Additionally, Mazabraud sold 55,803 shares at a weighted average price of $51.7217, with individual sales ranging from $51.31 to $52.04.
• Following these transactions, Mazabraud directly owns 40,370 shares of Rhythm Pharmaceuticals common stock.
• Mazabraud also continues to hold options for 25,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine insider transactions under a pre-arranged plan, which doesn't necessarily indicate positive or negative sentiment about the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of these sales mitigates this risk.

Industry Context

Insider transactions are a normal part of corporate activity. Monitoring these transactions provides insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 plan suggests a planned and orderly approach to these transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales should mitigate any significant concerns.

Key Dates